Cramer Rosenthal Mcglynn LLC Buys 246,269 Shares of Natus Medical Inc (NASDAQ:BABY)

Cramer Rosenthal Mcglynn LLC boosted its stake in shares of Natus Medical Inc (NASDAQ:BABY) by 19.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,534,996 shares of the medical equipment provider’s stock after purchasing an additional 246,269 shares during the quarter. Cramer Rosenthal Mcglynn LLC’s holdings in Natus Medical were worth $39,434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. BSW Wealth Partners acquired a new stake in Natus Medical in the second quarter worth about $27,000. Royce & Associates LP lifted its holdings in shares of Natus Medical by 55.4% during the first quarter. Royce & Associates LP now owns 1,100 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 392 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Natus Medical during the second quarter worth about $50,000. US Bancorp DE lifted its holdings in shares of Natus Medical by 71.8% during the second quarter. US Bancorp DE now owns 4,287 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 1,791 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Natus Medical during the first quarter worth about $114,000. 91.56% of the stock is currently owned by institutional investors.

A number of equities research analysts recently commented on the company. Zacks Investment Research raised Natus Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, June 26th. BidaskClub raised Natus Medical from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $36.00.

In other news, Director Ken Ludlum sold 12,632 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $31.94, for a total value of $403,466.08. Following the completion of the sale, the director now directly owns 39,406 shares in the company, valued at $1,258,627.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Austin Francis Noll III sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $31.14, for a total value of $622,800.00. Following the completion of the sale, the vice president now owns 105,193 shares of the company’s stock, valued at $3,275,710.02. The disclosure for this sale can be found here. 1.65% of the stock is currently owned by company insiders.

Shares of Natus Medical stock remained flat at $$31.92 on Friday. The company had a trading volume of 289,334 shares, compared to its average volume of 165,325. The company has a fifty day simple moving average of $29.31 and a 200 day simple moving average of $26.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.70 and a quick ratio of 1.18. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 22.48 and a beta of 0.57. Natus Medical Inc has a 12-month low of $23.53 and a 12-month high of $37.90.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.04. The company had revenue of $125.50 million during the quarter, compared to analysts’ expectations of $122.85 million. Natus Medical had a positive return on equity of 10.79% and a negative net margin of 7.38%. Natus Medical’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period last year, the business earned $0.35 earnings per share. On average, research analysts predict that Natus Medical Inc will post 1.27 earnings per share for the current fiscal year.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: Call Option

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.